Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

British Journal of Haematology

Volumn 169, Issue 2, 2015, Pages 219-227

  Mikhael, Joseph R ^a   Reeder, Craig B ^a   Libby, Edward N ^b   Costa, Luciano J ^c   Bergsagel, P Leif ^a   Buadi, Francis ^d   Mayo, Angela ^a   Nagi Reddy, Sravan K ^a   Gano, Katherine ^a   Dueck, Amylou C ^a   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

^b USA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Clinical studies; Clinical trials; Experimental therapies; Multiple myeloma; Myeloma therapy

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALANINE AMINOTRANSFERASE; ANTIINFECTIVE AGENT; CARFILZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LOW MOLECULAR WEIGHT HEPARIN; PLERIXAFOR; THALIDOMIDE; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STEM CELL; CANCER SURVIVAL; CARDIOTOXICITY; CONSTIPATION; COUGHING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LETHARGY; LEUKOCYTOSIS; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; AGED; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; OLIGOPEPTIDES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84926420960     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13296     Document Type: Article

References (22)

1. Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. British Journal of Haematology, 102, 1115-1123.
2. Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., de Vivo, A., Testoni, N., Nicci, C., Terragna, C., Grafone, T., Perrone, G., Ceccolini, M., Tura, S. & Baccarani, M.; Bologna 2002 study. (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood, 106, 35-39.
3. Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P. & Baccarani, M.; GIMEMA Italian Myeloma Network. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, 376, 2075-2085.
4. Demo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., Shenk, K.D., Smyth, M.S., Sun, C.M., Vallone, M.K., Woo, T.M., Molineaux, C.J. & Bennett, M.K. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 6383-6391.
5. Jakubowiak, A.J., Dytfeld, D., Griffith, K.A., Lebovic, D., Vesole, D.H., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., Stockerl-Goldstein, K., Ahmed, A., Jobkar, T., Durecki, D.E., McDonnell, K., Mietzel, M., Couriel, D., Kaminski, M. & Vij, R. (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120, 1801-1809.
6. Khan, M.L., Reeder, C.B., Kumar, S.K., Lacy, M.Q., Reece, D.E., Dispenzieri, A., Gertz, M.A., Greipp, P., Hayman, S., Zeldenhurst, S., Dingli, D., Lust, J., Russell, S., Laumann, K.M., Mikhael, J.R., Leif Bergsagel, P., Fonseca, R., Vincent Rajkumar, S. & Keith Stewart, A. (2012) A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 156, 326-333.
7. Korde, N., Zingone, A., Kwok, M.L., Manasanch, E.E., Bhutani, M., Tageja, N., Kazandjian, D., Mailankody, S., Costello, R., Zhang, Y., Burton, D., Carter, G., Wu, P., Mulquin, M., Zuchlinski, D., Maric, I., Calvo, K.R., Braylan, R.C., Roschewski, M., Yuan, C., Stetler-Stevenson, M., Arthur, D.C., Lindenberg, L., Kurdziel, K., Choyke, P., Steinberg, S.M. & Landgren, O. (2013) Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients. Blood, 122, Abstract 538.
8. Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Demo, S.D., Bennett, M.K., van Leeuwen, F.W., Chanan-Khan, A.A. & Orlowski, R.Z. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 3281-3290.
9. Kumar, S.K., Mikhael, J.R., Buadi, F.K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M.A., Greipp, P.R., Hayman, S.R., Kyle, R.A., Lacy, M.Q., Lust, J.A., Reeder, C.B., Roy, V., Russell, S.J., Short, K.E., Stewart, A.K., Witzig, T.E., Zeldenrust, S.R., Dalton, R.J., Rajkumar, S.V. & Bergsagel, P.L. (2009) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clinic Proceedings, 84, 1095-1110.
10. Kumar, S., Flinn, I., Richardson, P.G., Hari, P., Callander, N., Noga, S.J., Stewart, A.K., Turturro, F., Rifkin, R., Wolf, J., Estevam, J., Mulligan, G., Shi, H., Webb, I.J. & Rajkumar, S.V. (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 119, 4375-4382.
11. Kyle, R.A. & Rajkumar, S.V. (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 23, 3-9. [Erratum, Leukemia 2014, 28, 980.]
12. Mikhael, J.R., Dingli, D., Roy, V., Reeder, C.B., Buadi, F.K., Hayman, S.R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R.A., Lin, Y., Russell, S.J., Kumar, S., Bergsagel, P.L., Zeldenrust, S.R., Leung, N., Drake, M.T., Kapoor, P., Ansell, S.M., Witzig, T.E., Lust, J.A., Dalton, R.J., Gertz, M.A., Stewart, A.K., Rajkumar, S.V., Chanan-Khan, A. & Lacy, M.Q.; Mayo Clinic. (2013) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proceedings, 88, 360-376.
13. Palumbo, A., Facon, T., Sonneveld, P., Bladè, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., Boccadoro, M. & Harousseau, J.L. (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 111, 3968-3977.
14. Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., Patriarca, F., Levi, A., Benevolo, G., Vincelli, I.D., Grasso, M., Franceschini, L., Gottardi, D., Zambello, R., Montefusco, V., Falcone, A.P., Omedé, P., Marasca, R., Morabito, F., Mina, R., Guglielmelli, T., Nozzoli, C., Passera, R., Gaidano, G., Offidani, M., Ria, R., Petrucci, M.T., Musto, P., Boccadoro, M. & Cavo, M. (2014) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of Clinical Oncology, 32, 634-640.
15. Papadopoulos, K.P., Siegel, D.S., Vesole, D.H., Lee, P., Rosen, S.T., Zojwall, N., Holahan, J.R., Lee, S., Wang, Z. & Badros, A. (2014) A phase 1 study of a 30-minute infusion of carfilzomib alone or with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. Journal of Clinical Oncology, doi:10.1200/jco.2013.52.3522
16. Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. & Witzig, T.E. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology, 20, 4319-4323.
17. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P.R.; Eastern Cooperative Oncology Group. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431-436.
18. Rajkumar, S.V., Rosiñol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J.B. & Bladé, J. (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, 2171-2177.
19. Roussel, M., Robillard, N., Moreau, P., Benboubker, L., Hulin, C., Marit, G., Lelau, X., Pegourie, B., Fruchart, C., Caillot, D., Stoppa, A.M., Facon, T., Wuilleme, S., Avet-Loiseau, H. & Attal, M. (2011) Bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: updated results of the IFM 2008 phase II VRD intensive program. Blood, 118, Abstract 1872.
20. Shah, J.J., Stadtmauer, E.A., Abonour, R., Cohen, A.D., Bensinger, W., Gasparetto, C., Kaufman, J.L., Lentzsch, S., Vogl, D.T., Orlowski, R.Z., Kim, E.L., Bialas, N., Smith, D.D. & Durie, B.G.M. (2013) Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Blood, 122, Abstract 690.
21. Sonneveld, P., Asselberg-Hacker, E., Zweegman, S., van der Holt, B., Kersten, M.J., Vellenga, E., van Marwijk Kooy, M., de Weerdt, O., Lonergan, S., Palumbo, A. & Lokhorst, H. (2013) Dose escalation phase 2 trial of carfilzomib combined with thalidomide and low-dose dexamethasone in newly diagnosed, transplant eligible patients with multiple myeloma. A trial of the European Myeloma Network. Blood, 122, Abstract 688.
22. Yarde, D.N., Oliveira, V., Mathews, L., Wang, X., Villagra, A., Boulware, D., Shain, K.H., Hazlehurst, L.A., Alsina, M., Chen, D.T., Beg, A.A. & Dalton, W.S. (2009) Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Research, 69, 9367-9375.